Summary of THERAGENICS CORP

Entry into a Material Definitive Agreement, Creation of a Direct Financial Oblig

Item 1.01 Entry into a Material Definitive Agreement

On October 10, 2012, Theragenics Corporation and its subsidiaries (collectively, the "Company") executed a Second Amended and Restated Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association ("Wells Fargo"). The Credit Agreement provides for up to $40 million of borrowings under a revolving credit facility (the "Revolver"). The Revolver matures on October 10, 2015 with interest on outstanding borrowings payable at the London Interbank Offered Rate ("LIBOR") plus 1.75%. The Revolver also provides for a $5 million sub-limit for trade and stand-by letters of credit. The Credit Agreement is unsecured, but provides for a lien to be established on substantially all assets of the Company upon certain events of default. The Credit Agreement contains representations and warranties, as well as affirmative, reporting and negative covenants customary for financings of this type. Among other things, the Credit Agreement restricts the incurrence of certain additional debt and requires the maintenance of certain financial ratios, including a minimum fixed charge coverage ratio, a maximum senior liabilities to tangible net worth ratio, and the maintenance of minimum liquid assets of $10 million, as all such ratios and terms are defined in the Credit Agreement. At October 10, 2012, outstanding borrowings totaled $22 million under the Revolver and outstanding letters of credit totaled approximately $946,000. The obligations of Theragenics Corporation and each of its subsidiaries under the Credit Agreement, as co-borrowers, are joint and several.

The Credit Agreement described above amends and restates the May 27, 2009 credit agreement with Wells Fargo (as successor to Wachovia Bank), which was scheduled to mature on October 31, 2012 and provided for a $30 million revolving loan and letter of credit commitment.

The above description is a summary of the material terms of the Credit Agreement. This description is qualified by reference to the full text of the Credit Agreement, which is attached as Exhibit 10.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d)      Exhibits

Exhibit  Document
Number

10.1     Second Amended and Restated Credit Agreement dated as of October 10,
         2012 among the Company, C.P. Medical Corporation, Galt Medical Corp.,
         NeedleTech Products, Inc. and Wells Fargo, together with related Second
         Amended and  Restated and Consolidated Line of Credit Note.